LEADERSHIP

Dr. Yuxuan Wu is the co-founder and CEO of YolTech Therapeutics, where he drives the development of next-generation in vivo gene-editing therapies using LNP-mRNA delivery. To date, YolTech has advanced multiple therapeutic programs into clinical stage, with a diversified pipeline spanning genetic, metabolic, cardiovascular diseases.

Prior to YolTech, Dr. Wu co-founded BRL Medicine and developed BRL-101, a CRISPR-based therapy for patients with transfusion-dependent β-thalassemia, which achieved excellent efficacy (Nature Medicine, 2022). From 2015 to 2018, he worked at Harvard Medical School, where he contributed to the development of a CRISPR/Cas9-based editing system for hematopoietic stem cells to treat hemoglobin disorders by reactivating fetal hemoglobin expression (Nature Medicine, 2019, 2020).

Dr. Wu holds a Ph.D. in Cell Biology from Wuhan University.

Dr. Emma Wang brings to YolTech more than 10 years of experience in the pharmaceutical and biotechnology industry. Prior to YolTech, Emma spent more than five years working in mRNA/LNP drug product development, formulation development, process and analytical development, technical transfer, CMC strategy at Beam, Tessera and Providence Therapeutics.  

As chief development and technical officer at YolTech, Emma oversees platform and pipeline research activities and manages a multidisciplinary team in drug product development, CMC, manufacturing, regulatory affairs, quality and early clinical development. She holds a B.Eng and M.Eng in Chemical Engineering from McGill University in Canada and Ph.D in Chemistry from Max Planck Institute for Polymer Research in Germany. 

Dr. Yuming Lu leads gene editing at YolTech and brings 10+ years of CRISPR tool development and biotech startup experience.

Prior to YolTech, he founded BIOGLE Gene, a biotechnology company providing gene-editing solutions to research and industry partners. He previously served as a Distinguished Principle Investigator at the Chinese Academy of Sciences and led multiple national research programs.

Dr. Lu has published in top-tier journals including Nature Biotechnology, with a focus on CRISPR tool innovation and its applications.